Avalo Therapeutics (AVTX) earnings, Nov 5, 2026: EPS +84%, stock −6.2%
In brief
Avalo Therapeutics reported on Nov 5, 2026. Earnings per share changed +84% year over year, 42.2% above the estimate; revenue 0%. The stock opened with a −4.4% gap and closed the day −6.2% (Nov 5, 2026). The stock is now 72.7% below its 52-week high, −59.7% over 12 months.
EPS vs estimate+42.2%
EPS, YoY+84%
Revenue, YoY0%
Gap · day−4.4% · −6.2%
EPS growth by quarter, YoY
Price reaction to earnings
| Report | Gap | Day |
|---|---|---|
| Aug 6, 2026 | −5.1% | −0.7% |
| Nov 5, 2026 | −4.4% | −6.2% |
Next-quarter estimates, ratings and the AVTX chart are in the terminal.
Open the terminalFAQ
When is Avalo Therapeutics's next earnings report?
There is no new date in the data yet: companies announce it a few weeks ahead.
How did Avalo Therapeutics stock react to the report?
Opening gap −4.4%, day's result −6.2%.
Did Avalo Therapeutics's earnings grow?
Earnings per share rose 84% year over year.
What is an earnings gap?
The jump between the close before and the open after the report. A big gap up often means large buyers are revaluing the company.